Skip to content Skip to footer
Subscribe Now
Abbvie
NEWS

AbbVie Reports the US FDA’s BLA Submission of Pivekimab Sunirine to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm

Shots:The US FDA has received BLA of Pivekimab sunirine (PVEK) for the treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)The BLA is backed by the P-I/II (CADENZA) trial, which evaluated PVEK monotx. to establish the MTD, RP2D, & dosing schedule, while assessing safety, tolerability, PK, immunogenicity, & antileukemia activity in pts with CD123+…
October 1, 2025

Read more

VIEWPOINTS

Combating Hematologic Malignancies: Dr. Petri Bono from Faron Pharmaceuticals in Conversation with PharmaShots 

Shots:  Myelodysplastic Syndrome (MDS) is a rare and aggressive blood cancer in which the bone marrow fails to produce enough healthy blood cells As resistance to traditional treatments continues to rise among MDS patients, Faron Pharmaceuticals' Bexmab emerges as a promising alternative Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, highlights Bexmab’s unique mechanism…
July 30, 2025

Read more

VIEWPOINTS

Next-Gen T Cell Engagers for Solid Tumors: Shaun Murphy in a Riveting Dialogue Exchange with PharmaShots

Shots:  Unlike hematologic malignancies, where the elimination of most or all tumor cells results in immunosuppression, making headways in solid tumors requires a new holistic approach when using T Cell Engagers Abpro’s ABP-102/CT-P72, co-developed by Celltrion leverages a tetravalent format; bivalent for both HER2 and CD3 PharmaShots welcomes Shaun Murphy, Vice President, Nonclinical Research and…
July 21, 2025

Read more

VIEWPOINTS_Michael Moran1_Julie Blaedel2_2024
VIEWPOINTS

Julie Blaedel from Genmab and Michael Moran from AbbVie Discuss the Conditional EC Approval of TEPKINLY in a Stimulating Conversation with PharmaShots

Shots:   Diffuse large B-cell lymphoma remains the most common type of non-Hodgkin lymphoma. With limited therapeutic options for patients whose disease gets relapsed or refractory, AbbVie and Genmab’s TEPKINLY is one-of-a-kind monotherapy for adult patients with relapsed or refractory DLBCL  Post EC’s conditional approval, Julie Blaedel & Michael Moran engage in an enlightening conversation with…
January 10, 2024

Read more